SHARPE·IQStart free
Menu
TodayResearchEarningsToolsPricingSign in
INDV reported Q3 2026 results. The stock moved +1.4% on the print.
INDVearnings

Earnings reactions, page 9

Indivior Pharmaceuticals, Inc. (INDV) Q3 FY2026 earnings

October 29, 2026 · SharpeIQ Research Desk

Reported results

  • Total net revenue was $356 million for the third quarter of 2026.
  • Total SUBLOCADE net revenue was $267 million for the third quarter of 2026.
  • GAAP net income was $137 million for the third quarter of 2026.
  • Non-GAAP net income was $161 million for the third quarter of 2026.
  • Adjusted EBITDA was $211 million for the third quarter of 2026.
  • Non-GAAP operating expenses were $103 million for the third quarter of 2026.

Guidance

  • Full-Year 2026 Net Revenue: $1,295 million to $1,365 million
  • Full-Year 2026 Total SUBLOCADE Net Revenue: $1,010 million to $1,050 million
  • Full-Year 2026 Non-GAAP Operating Expenses: $430 million to $450 million
  • Full-Year 2026 Adjusted EBITDA: $700 million to $740 million

Notes

The company expects to close its merger with Supernus on November 2, 2026, at which time the guidance will no longer apply.

Price and volatility reaction

The stock moved +1.4% on the print. No front-expiry chain was on file, so there is no straddle expected move. 30-day ATM implied volatility moved -20.8 vol points across the event (constant-maturity series — not the front-week crush).

MeasureValueBasis
Close before release34.772026-10-28
Close after release35.252026-10-29
Realised move+1.4%close to close
30d ATM IV change-20.8 vol ptsconstant-maturity series, not the front expiry
Price and volatility reaction. Closes either side of the release. No front-expiry chain on file for a straddle expected move. SharpeIQ — listed option chain and price_history

Source

The figures above come from the earnings release the company filed with the SEC on 2026-10-29 (8-K, Item 2.02). Read the original filing on sec.gov.

See this live in SharpeIQ

IV rank, historical IV and the single-ticker tools. The scanner and AI research are paid plans.

Open IV Rank →